-
公开(公告)号：US20220370611A1
公开(公告)日：2022-11-24
申请号：US17529450
申请日：2021-11-18
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , In-Cheol SUN , Man Kyu SHIM , Ji Woong CHOI
IPC: A61K41/00 , A61P35/00 , A61K31/351 , A61K47/69
Abstract: Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.
-
公开(公告)号：US20240159744A1
公开(公告)日：2024-05-16
申请号：US18041587
申请日：2021-08-12
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Inventor： Ju Hee RYU , Ick Chan KWON , Kwangmeyung KIM , Han Young KIM , Eun-sun KIM
IPC: G01N33/542 , A61K47/64 , G01N33/574 , G01N33/68
CPC classification number: G01N33/542 , A61K47/642 , G01N33/57419 , G01N33/6893 , G01N2333/485
Abstract: The present disclosure relates to a cancer cell-specific complex for targeting cancer. The complex for targeting cancer according to the present disclosure includes EGF, but is affected more by lysosomal activity rather than the EGFR signaling pathway, and thus can overcome the shortcomings of the existing EGF therapy-based diagnostic and therapeutic compositions and provide successfully personalized and improved effects of treating, preventing and alleviating cancer.
A diagnostic composition according to the present disclosure enables the prediction of the anticancer performance of a therapeutic composition of the present disclosure in a subject, and thus enables anticancer treatment to be designed stably.-
3.发明公开公开(公告)号：US20230173083A1
公开(公告)日：2023-06-08
申请号：US17735371
申请日：2022-05-03
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , Hong Yeol YOON , In-Cheol SUN , Man Kyu SHIM , Hanhee CHO
IPC: A61K47/64 , A61K47/65 , A61K31/704 , A61P35/00
CPC classification number: A61K47/643 , A61K31/704 , A61K47/65 , A61P35/00
Abstract: Disclosed is a prodrug for preventing or treating cancer. The prodrug is mediated by albumin present in the blood to achieve high cancer selectivity for cancer and high stability. Also disclosed is a pharmaceutical composition for preventing or treating cancer including the prodrug. The anticancer prodrug and the pharmaceutical composition form a conjugate with albumin even without using a carrier or delivery vector when injected in vivo. Therefore, the anticancer prodrug and the pharmaceutical composition are effective in preventing or treating cancer, have increased in vivo half-lives, and can accumulate in cancer with increased efficiency to significantly alleviate the side effects of the anticancer drug.
-
4.发明公开公开(公告)号：US20230293719A1
公开(公告)日：2023-09-21
申请号：US17859078
申请日：2022-07-07
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , In-Cheol SUN , Hong Yeol YOON , Man Kyu SHIM , Suah YANG
CPC classification number: A61K47/6915 , A61K47/64 , A61P35/00
Abstract: Disclosed is an optimal peptide-liposome complex capable of multivalent crosslinking with PD-L1 on the cell surface to induce degradation of PD-L1. The peptide-liposome complex effectively blocks PD-L1, an immune checkpoint on the surface of cancer cells, and prevents the recycling of PD-L1 by intracellular metabolism to induce complete degradation of PD-L1 in cancer cells, achieving an increased therapeutic effect on cancer.
-
公开(公告)号：US20210015931A1
公开(公告)日：2021-01-21
申请号：US16573351
申请日：2019-09-17
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Sun Hwa KIM , Ick Chan KWON , In-San KIM , Kwangmeyung KIM , Yoosoo YANG , Young-Ji KO
IPC: A61K47/55 , A61K47/54 , A61K31/713 , A61P35/00 , C12N15/113 , C07K14/705
Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.
-
Patent Agency Ranking
公开(公告)号：US20190083637A1
公开(公告)日：2019-03-21
申请号：US15925830
申请日：2018-03-20
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , Ick Chan KWON , Juho PARK
IPC: A61K47/64 , A61K47/69 , A61K31/704 , A61K9/51
Abstract: Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.
-
公开(公告)号：US20200071698A1
公开(公告)日：2020-03-05
申请号：US16425849
申请日：2019-05-29
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Sun Hwa KIM , Ick Chan KWON , Kwangmeyung KIM , Hong Yeol YOON , Gi-Jung KWAK , Juho PARK
IPC: C12N15/113 , A61P35/00
Abstract: The present invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which comprises an anti-miRNA single-stranded nucleic acid having a nucleic acid sequence complementary to a nucleic acid sequence of an miRNA. Further, the present invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate in which serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group.
-
8.发明申请公开(公告)号：US20170216460A1
公开(公告)日：2017-08-03
申请号：US15169493
申请日：2016-05-31
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , Ju Hee RYU , Ick Chan KWON , Man Kyu SHIM , Hong Yeol YOON
IPC: A61K49/00 , G01N33/58 , G01N33/574 , C07K9/00
CPC classification number: A61K49/0056 , A61K47/555 , A61K49/0032 , A61K49/0052 , C07K5/1016 , C07K5/1019 , C07K9/001 , G01N33/57496 , G01N33/581 , G01N2333/96466
Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.
-
公开(公告)号：US20210179681A1
公开(公告)日：2021-06-17
申请号：US17118767
申请日：2020-12-11
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , Ju Hee RYU , Hong Yeol YOON , Man Kyu SHIM , Suah YANG
Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.-
公开(公告)号：US20190201538A1
公开(公告)日：2019-07-04
申请号：US15944025
申请日：2018-04-03
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , Ick Chan Kwon , Juho Park
CPC classification number: A61K47/546 , A61K41/0071 , A61K47/55 , A61K47/65 , A61K47/6929 , A61P35/00
Abstract: Disclosed is a tumor-targeting photosensitizer-drug conjugate, more particularly to one which exhibits superior specific activity for a tumor tissue, is effectively accumulated in the tumor tissue and exhibits the medicinal effect of an anticancer agent with little systemic toxicity as a DEVD peptide is cleaved by caspase-3 and released topically from a prodrug form.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.016 seconds)
